Toronto Dominion Bank
KYMR icon

Toronto Dominion Bank’s Kymera Therapeutics KYMR Stock Holding History

Toronto Dominion Bank’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-26,791
Closed -$1.7M – 1721
2021
Q4 		$1.7M Buy
+26,791
New +$1.56M ﹤0.01% 883

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Toronto Dominion Bank's KYMR Position: Q1 2022 in Review

Toronto Dominion Bank sold out of Kymera Therapeutics (KYMR) in Q1 2022, closing a stake of 26,791 shares — an estimated $1.7M sold.

Toronto Dominion Bank first reported a position in KYMR in Q4 2021 and held it in 1 quarter. The position peaked at $1.7M in Q4 2021. 126 funds tracked by Wall St. Rank hold KYMR as of Q1 2022.

  • Toronto Dominion Bank reported no remaining Kymera Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Toronto Dominion Bank sold 26,791 Kymera Therapeutics shares in Q1 2022, an estimated $1.7M.
  • Toronto Dominion Bank first reported a position in Kymera Therapeutics in Q4 2021 and held it in 1 quarter.
  • Toronto Dominion Bank's Kymera Therapeutics position peaked at $1.7M in Q4 2021.
  • 126 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2022.

Based on Toronto Dominion Bank's 13F filing for Q1 2022, filed 9 May 2022.